Xarelto

Type: Product
Name: Xarelto
First reported 8 hours ago - Updated 7 hours ago - 1 reports

Why Johnson & Johnson's Patent Expiration Profile Is Fantastic

SummaryVery few firms have a more attractive investment profile than Johnson & Johnson. Johnson & Johnson boasts a cash-flow-derived Valuentum Dividend Cushion score of 2.2, and we don’t see us removing it from the Dividend Growth portfolio anytime soon. ... [Published Seeking Alpha - 8 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Bayer : Response to article in German news magazine “Der Spiegel“ from April 19, 2014

the German news magazine "Der Spiegel" has published an article under the headline "Control is better" that references a number of anticoagulants, including Xarelto from Bayer. In the article, the hypothesis is put forward that the benefits of Xarelto ... [Published 4 Traders - 20 hours ago]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Continuing warfarin in ablations reduces periprocedural stroke risk

Keeping patients with atrial fibrillation on rather than off warfarin therapy during radiofrequency catheter ablation reduced the risk of periprocedural stroke in a randomized trial. The results were published online April 17 in Circulation .Thromboembolic ... [Published Cardiovascular Business - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 2 reports

Surveyed U.S. Physicians Expect Strong Uptake Of Novel Oral Anticoagulants For The Treatment Of VTE

BURLINGTON, Mass.Other key findings from the U.S. Physician and Payer Forum report entitled : Physicians indicate that they are unwilling to increase the duration of therapy for the treatment of either deep vein thrombosis or pulmonary embolism, despite ... [Published TheStreet.com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Bayer Q1 results: UBS expects strong CropScience phasing, HealthCare in line

Consensus trending upwards towards our estimate; strong CropScience 1Q Bayer consensus released on Tuesday (Vara Research) shows increasing optimism for 1Q results (28th April): underlying EBITDA (€2,588m) has risen 4% since post-FY consensus – driven ... [Published Invezz - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

J&J 1Q net up 8 percent on sales jump

The world’s biggest maker of health-care products beat Wall Street expectations and raised its earnings outlook Tuesday. The maker of Band-Aids and biologic drugs said net income was $4.73 billion, or $1.64 per share, up from $3.5 billion, or $1.22 per ... [Published Northwest Herald - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump

German drugmaker reports sales off 4.3% in 2013ShareToolsPradaxa may not be leading the new-age anticoagulant market, but it's certainly leading Boehringer Ingelheim's growth efforts. The blockbuster med made significant gains in 2013 to help offset currency ... [Published FiercePharma - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Taking Blood Thinners With Certain Painkillers May Raise Bleeding Risk: MedlinePlus

People using warfarin or Xarelto should avoid aspirin, ibuprofen and other NSAIDs, study finds MONDAY, April 14, 2014 (HealthDay News) -- People taking blood thinners to prevent clots in their legs or lungs may put themselves at risk for serious internal ... [Published DailyMe.Com - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

J&J hits one-week high as Q1 earnings beat, 2014 forecast boosted

3:52 pm by The company credited strong sales of new drugs: prostate cancer pill Zytiga ($512 million), hepatitis C medicine Olysio ($354 million) and Xarelto for preventing strokes ($319 million). Each is on pace to become blockbusters exceeding $1 billion ... [Published Proactive Investors USA - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday-or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, ... [Published FiercePharma - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Taking NSAIDs with blood thinners ups bleeding risk

People taking Read: One-quarter of these major bleeds happen within eight days of taking an NSAID, Davidson said. "It's not like you have to be taking them for weeks or months. Some bleeds happen with a single dose," he said.Anticoagulant therapyIt's ... [Published Health24 - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Blood Thinner Blamed For Hundreds Of Injuries, Deaths In Lawsuit

The pharmaceutical company behind the anticoagulant drug Xarelto is facing a lawsuit from a New Jersey woman who claims that her aunt died as a result of using the blood thinner.Della Wise charges that Janssen Research & Development and Bayer Corp. acted ... [Published Medical Daily - Apr 14 2014]

Quotes

While the overall bleeding rates are low and the rates of serious life-threatening bleeding even lower, "when something does happen, you can be in a real"
"Given the company's strong financial position as demonstrated by its AAA debt rating, its strong cash flow generation and track record of consistently raising the dividend, we expect Johnson & Johnson to continue to grow the dividend in line with earnings, at a rate of 7 per cent per year, on average" Edward Jones analyst Judson Clark said in a note
...by successful new product launches and the continued growth of key products," said Alex Gorsky ( pictured ), chairman and chief executive, adding: "Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results."
Edward Jones analyst Judson Clark predicted "earnings growth will accelerate over the next few years, driven primarily by new biopharmaceutical product launches and a decreasing impact from patent losses" which trigger generic competition

More Content

All (138) | News (114) | Reports (0) | Blogs (21) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Why Johnson & Johnson's Patent Expiration Profi... [Published Seeking Alpha - 8 hours ago]
Bayer : Response to article in German news maga... [Published 4 Traders - 20 hours ago]
Target-Specific Oral Anticoagulants [Published U.S.Pharmacist - Apr 18 2014]
Continuing warfarin in ablations reduces peripr... [Published Cardiovascular Business - Apr 18 2014]
Earnings Roundup: Johnson & Johnson Results Are... [Published Motley Fool - Apr 17 2014]
Tracklist: Beyonce and Jay Z, parents on tour [Published Creative Loafing - Apr 17 2014]
Surveyed U.S. Physicians Expect Strong Uptake O... [Published TheStreet.com - Apr 17 2014]
Surveyed U.S. Physicians Expect Strong Uptake o... [Published BusinessWeek - Apr 17 2014]
Bayer Q1 results: UBS expects strong CropScienc... [Published Invezz - Apr 17 2014]
Pharma driving J&J sales [Published Pharmafocus - Apr 17 2014]
A 'Real Bind': One Center Takes on Dabigatran B... [Published General Medicine eJournal - Apr 16 2014]
A prescription for a healthy dividend [Published GlobeAdvisor - Apr 16 2014]
Johnson & Johnson 1st-qtr 2014 results beat exp... [Published Pharma Letter - Apr 16 2014]
J&J 1Q net up 8 percent on sales jump [Published Northwest Herald - Apr 15 2014]
Taking Blood Thinners With Certain Painkillers ... [Published DailyMe.Com - Apr 15 2014]
J&J hits one-week high as Q1 earnings beat, 201... [Published Proactive Investors USA - Apr 15 2014]
Johnson & Johnson's Management Discusses Q1 201... [Published Seeking Alpha - Apr 15 2014]
J&J’s Pharmaceutical Success Drives Increase in... [Published Washington Post - Apr 15 2014]
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
J&J Q1 net up 8 percent on sales jump, lower costs [Published Investor's Business Daily - Apr 15 2014]
Boehringer Ingelheim revenue slide cushioned by... [Published FiercePharma - Apr 15 2014]
J&J Earnings Beat Estimates As Pharma Sales Shine [Published Investor's Business Daily - Apr 15 2014]
New drugs are J&J's Q1 heroes, spurring pharma ... [Published FiercePharma - Apr 15 2014]
Tuesday’s Top Health Care Stories: Johnson & Jo... [Published Motley Fool - Apr 15 2014]
Johnson & Johnson Lifts FY14 Earnings Forecast ... [Published RTTNews.com - Apr 15 2014]
Johnson & Johnson's sales increase 3.5% to $18.... [Published News-Medical.Net - Apr 15 2014]
Johnson & Johnson Reports 2014 First-Quarter Re... [Published PharmaceuticalProcessing - Apr 15 2014]
Taking NSAIDs with blood thinners ups bleeding ... [Published Health24 - Apr 15 2014]
UPDATE 1-Boehringer 2013 profit up on Pradaxa s... [Published Reuters UK - Apr 15 2014]
Blood Thinner Blamed For Hundreds Of Injuries, ... [Published Medical Daily - Apr 14 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
Source: http://www.flickr.com/photos/59937401@N07/ Shares of  Johnson & Johnson  ( NYSE:JNJ ) jumped as much as 1.6 percent in early trading on Tuesday after the healthcare and pharmaceutical company reported strong first-quarter results . Sales ...
Taking Blood Thinners with Certain Painkillers ... [Published MedlinePlus Health News - Apr 14 2014]
People using warfarin or Xarelto should avoid aspirin, ibuprofen and other NSAIDs, study finds Source: HealthDayRelated MedlinePlus Pages: Bleeding , Blood Thinners , Pain Relievers ...
Janssen Expands the EXPLORER Global Cardiovascu... [Published PR Newswire: Health - Mar 31 2014]
RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban), the most studied and ...
Bristol-Myers and Pfizer Win Approval of New In... [Published Wall St. Cheat Sheet - Mar 14 2014]
Bristol-Myers Squibb & Co.  ( NYSE:BMY ) and Pfizer Inc. ( NYSE:PFE )  announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. The drug is now approved for the prevention of blood ...
Bayer says Xarelto and Eylea drugs near peak sa... [Published Yahoo! Health News - Feb 28 2014]
LEVERKUSEN, Germany (Reuters) - German drugmaker Bayer expects Xarelto and Eylea, among its most promising drugs, to be near their peak sales potential in about 5 to 6 years, Chief Executive Marijn Dekkers told a news conference on Friday. He adde... ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Portola Pharmaceuticals Enters Into Clinical Co... [Published GlobeNewswire: Earnings News - Feb 03 2014]
Portola Pharmaceuticals Announces Additional Po... [Published GlobeNewswire: Advertising News - Nov 11 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.